VERU

VERU

USD

Veru Inc. Common Stock

$2.650+0.070 (2.713%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$2.580

Máximo

$2.650

Mínimo

$2.580

Volumen

0.18M

Fundamentos de la Empresa

Capitalización de Mercado

42.5M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.18M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $2.42Actual $2.650Máximo $14.2

Informe de Análisis de IA

Última actualización: 10 nov 2025
Generado por IAFuente de Datos: Yahoo Finance, Bloomberg, SEC

VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges

Market Snapshot

Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns


Recent Performance: Turbulent Descent

Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:

  • Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
  • Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
  • Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.

Technical Signals: Mixed Messages

  • Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
  • Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
  • MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.

Fundamentals: Value Trap or Hidden Potential?

  • Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
  • **High-Risk

Noticias Relacionadas

GlobeNewswire

Veru to Present Two Abstracts at ObesityWeek 2025

MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Ver más
Veru to Present Two Abstracts at ObesityWeek 2025
GlobeNewswire

Veru Announces Pricing of $25 Million Public Offering

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Ver más
Veru Announces Pricing of $25 Million Public Offering

Predicción de IABeta

Recomendación de IA

Alcista

Actualizado el: 10 nov 2025, 14:42

BajistaNeutralAlcista

58.4% Confianza

Riesgo y Negociación

Nivel de Riesgo3/5
Riesgo Medio
Adecuado Para
Valor
Guía de Negociación

Punto de Entrada

$2.52

Toma de Ganancias

$2.61

Stop Loss

$2.30

Factores Clave

PDI 15.4 está por encima de MDI 14.1 con ADX 19.0, lo que sugiere una tendencia alcista
El volumen de operaciones es 1.9 veces el promedio (3,174), lo que indica una mayor participación en el mercado
El MACD 0.0119 está por debajo de la línea de señal 0.0162, lo que indica un cruce bajista

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.